Patent ID: 6863885
Filing Date: 2005-03-08
Classification: A61K,A61P

Abstract:
1. A method of engrafting allogenic donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a non-myeloablative amount of radiomimetic compound, comprising: a. administering to the recipient at least one dosage of a hematopoietic growth factor selected from the group consisting of granulocyte colony stimulating factor (GCSF), stem cell factor (SCF), granulocyte macrophage colony stimulating factor (GMCSF), interleukin-1 (IL-1), interleukin-3 (IL-3), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-11 (IL-11), interleukin-12 (IL-12), leukemia inhibitory factor (LIF), fibroblast growth factor-β(FGF-β) and FMS-like tyrosine kinase 3-ligand (FLT3-ligand), or a combination thereof; b. subjecting the recipient to the non-myeloablative amount of radio-mimetic compound; and, c. transplanting the hematopoietic pluripotent cells into the recipient, thereby engrafting the allogenic donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a non-myeloablative amount of radio-mimetic compound.